Cipher Capital’s PTC Therapeutics PTCT Stock Holding History

Cipher Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,704	Closed	-$267K	–	583
2023 Q4	$267K	Buy	+9,704	New	+$222K	0.09%	360

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cipher Capital's PTCT Position: Q1 2024 in Review

Cipher Capital sold out of PTC Therapeutics (PTCT) in Q1 2024, closing a stake of 9,704 shares — an estimated $267K sold.

Cipher Capital first reported a position in PTCT in Q4 2023 and held it in 1 quarter. The position peaked at $267K in Q4 2023. 183 funds tracked by Wall St. Rank hold PTCT as of Q1 2024.

Cipher Capital reported no remaining PTC Therapeutics position as of Q1 2024 after selling out during the quarter.
Cipher Capital sold 9,704 PTC Therapeutics shares in Q1 2024, an estimated $267K.
Cipher Capital first reported a position in PTC Therapeutics in Q4 2023 and held it in 1 quarter.
Cipher Capital's PTC Therapeutics position peaked at $267K in Q4 2023.
183 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2024.

Based on Cipher Capital's 13F filing for Q1 2024, filed 15 May 2024.